This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Sign in
Sign In or Register
Sign out

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Explore Content

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

A diagnostic-driven approach to IFIs

A diagnostic approach to treating invasive fungal infections can aid early treatment of patients as well as improving the chances of survival1-4,6. 

A diagnostic-driven approach allows early treatment (in neutropenic patients with or without fever)1-4

A combination of diagnostic assessments is recommended:5
​​​​​​​
  • Monitoring of galactomannan (GM) may be used in patients who have a relatively high probability (>5-10%) of developing invasive aspergillosis (IA)
  • Appropriate clinical and microbiological evaluation
  • High-resolution computed tomography (CT) imaging

    CT section of the lung with halo sign in a patient with haematological malignancy

    Adapted from Green RE et al, 20076

    A diagnostic-driven approach has the potential to help you improve patients' chances of survival6

    • Routine GM screening is shown to lead to the early initiation of antifungal therapy4
    • Initiating appropriate treatment on the basis of CT patterns has been shown to improve survival*6
    • Increased survival was observed in patients with pulmonary invasive aspergillosis who presented with a halo sign versus those with other imaging findings at Week 12: 71% vs 53%, respectively (p<0.01)6

    *Based on analysis of chest CT findings at presentation from a large series (n=235) of patients with invasive pulmonary aspergillosis (IPA), to assess the prevalence of a "halo sign" and to evaluate the clinical utility of this imaging finding for early identification and treatment of IPA6 

    Example of a diagnostic-driven antifungal therapy integrated care pathway7

    Image based on Agrawal S, et al. J Antimicrob Chemother. 2011; 66(Suppl 1): i45-53.
    ​​​​​​​
    *Check response on Day 7. If no response to treatment, further diagnosis is required; if patient responds to treatment, consider the duration of therapy, "step down" therapy, and outpatient follow up.

    †Multidisciplinary team input important at this stage.

    IFD, invasive fungal disease; IMD, invasive mould disease; PCR, polymerase chain reaction

    Prescribing Information for Cresemba (isavuconazole)

    Great Britain
    Cresemba (isavuconazole) 100mg hard capsules
    Cresemba (isavuconazole) 200mg powder for concentrate for solution for infusion 

    Northern Ireland
    ​​​​​​​    Cresemba (Isavuconazole) 100mg hard capsules and Cresemba (Isavuconazole) 200mg powder for concentrate for solution for infusion

    References:
    1. Rogers TR, et al. Br J Haematol. 2011; 153(6): 681–97.
    2. Freemantle N, et al. J Antimicrob Chemother. 2011; 66(Suppl 1): i25–35.
    3. de Pauw BE& Viscoli C. J Antimicrob Chemother. 2011; 66(Suppl 1): i55–8.
    4. Maertens J, et al. Clin Infect Dis. 2005; 41(9): 1242–50.
    5. Marchetti O et al. Bone Marrow Transplant. 2012; 47(6): 846–54.
    6. Greene RE, et al. Clin Infect Dis. 2007; 44(3): 373–9.
    7. Agrawal S, et al. J Antimicrob Chemother. 2011; 66(Suppl 1): i45-53.
    PP-CRB-GBR-1213. August 2021

    Free for Download

    Antifungal Stewardship: Diagnostics Summary.

    Download here

    ** This is an optional area where footnotes can live.

    Card Header

    The card body Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam.

    Card CTA

    ** This is an optional area where footnotes can live.

    Learn about aspergillosis lateral flow tests

    The card body Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam.

    Find out more

    ** This is an optional area where footnotes can live.

    Invasive aspergillosis and the ICU

    Underlying conditions in ICU patients

    Find out more

    ** This is an optional area where footnotes can live.

    Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store

    Adverse events should also be reported to Pfizer Medical Information on 01304 616161

    For UK Healthcare Professionals*

    These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

    I confirm that I am a healthcare professional* resident in the United Kingdom.

    If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

    *The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

    PP-PFE-GBR-3863. November 2021

    Yes

    No

    OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.This is an interstitial message to prompt a HCP before they login.

    If you have already registered with pfizerpro.co.uk and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

    Would you like to register or sign in now?